EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Second Career for p53 as A Broad-Spectrum Antiviral?

Joe B Harford

Viruses · 2023

DOI: 10.3390/v15122377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Joe B Harford. Beteiligte Einrichtung: SynerGene Therapeutics, Inc., Potomac, MD 20854, USA. Hauptthemen laut MEDLINE: COVID-19, Tumor Suppressor Protein p53, Virus Diseases, Viruses. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As the world exits the global pandemic caused by the previously unknown SARS-CoV-2, we also mark the 30th anniversary of p53 being named “molecule of the year” by Science based on its role as a tumor suppressor. Although p53 was originally discovered in association with a viral protein, studies on its role in preventing carcinogenesis have far overshadowed research related to p53′s role in viral infections. Nonetheless, there is an extensive body of scientific literature demonstrating that p53 is a critical component of host immune responses to viral infections. It is striking that diverse viruses have independently developed an impressive repertoire of varied mechanisms to counter the host defenses that are mediated by and through p53. The variety of ways developed by viruses to disrupt p53 in their hosts attests to the protein’s importance in combatting viral pathogens. The present perspective aims to make the case that p53 ought to be considered a virus suppressor in addition to a tumor suppressor. It is hoped that additional research aimed at more fully understanding the role of p53 in antiviral immunity will result in the world being better positioned for the next pandemic than it was when SARS-CoV-2 emerged to produce COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Tumor Suppressor Protein p53Virus DiseasesVirusesHumansAntiviral AgentsImmunity, InnateSARS-CoV-2Viral Proteins

Stichwörter der Autor:innen

TP53broad-spectrum antiviralgene therapyhost antiviral defensesinnate immunityp53tumor suppressor

Substanzen

Antiviral AgentsTumor Suppressor Protein p53Viral Proteins

Autor:innen und Institutionen

  • SynerGene Therapeutics, Inc., Potomac, MD 20854, USA.

Zitieren

APA

Harford, J. B. (2023). A Second Career for p53 as A Broad-Spectrum Antiviral?. Viruses. https://doi.org/10.3390/v15122377

Vancouver

Harford JB. A Second Career for p53 as A Broad-Spectrum Antiviral?. Viruses. 2023. doi:10.3390/v15122377

BibTeX
@article{Harford2023,
  author = {Harford, Joe B},
  title = {A Second Career for p53 as A Broad-Spectrum Antiviral?},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15122377}
}
Kostenlos starten →